Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 03, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, is presenting at the 35^th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, at 11:30 a.m. PST, at the Westin St. Francis Hotel, in San Francisco, California.

A webcast of Marrazzo’s presentation will be available live on www.sparktx.com on the "Events" section of the Investors page. A replay of the presentation will be available on the website for 90 days following the conference. To access his full presentation slide deck, please visit "Investor Presentations" on the Investors page.

In addition, Dan Faga, chief business officer, will participate in a panel discussion on “The coming of age of gene therapy and gene editing,” during the Biotech Showcase on Tuesday, Jan. 10, from 8-9 a.m. PST, at the Hilton San Francisco Union Square.

About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001, in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer (which also has received both breakthrough therapy and orphan product designations) and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.

Spark Therapeutics Corporate Contacts:	
Stephen W. Webster 				
Chief Financial Officer 				
Daniel Faga 					
Chief Business Officer				
(855) SPARKTX (1-855-772-7589)

Media Contact:
Dan Quinn
Ten Bridge Communication
(781) 475-7974
[email protected]